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Renal cell carcinoma (RCC) is notoriously chemoresistant. Current management of metastatic disease usually includes immunological
agents of which the most clearly evaluated is alpha interferon. Following the failure of such agents no clear second-line therapy exists.
The use of a novel combination of cisplatin, irinotecan and mitomycin may offer some palliative benefit in this situation. Thirty-three
patients with cytokine refractory RCC and documented progression and documented active progressive disease with performance
status 0–3 were enrolled. Therapy consisted of cisplatin 40mgm
 2 on day 1 and day 15, irinotecan 100mgm
 2 on day 1 and day
15, and mitomycin 6mgm
 2 on day 1 of a 28-day cycle. The results showed that one patient (3%) had a partial response, eight (24%)
had minor responses and nine (27%) had stable disease, overall 61% had symptomatic responses. Quality-of-life (QOL) assessment
did not change significantly during therapy. Seventy-one percent of those who had primary refractory disease to cytokine therapy
subsequently responded to IPM. The median progression-free interval was 4.8 months in this cohort on chemotherapy, compared to
3.9 months with their previous cytokine treatment. In conclusion, IPM produced symptomatic relief for a majority of patients with
cytokine refractory RCC without any deterioration in QOL. Disease stabilisation on radiological assessment and symptomatic
improvement were associated with prolonged survival. A degree of non-crossresistance to cytokine therapy was seen. IPM may be
considered in patients with renal cancer following failure of cytokines.
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Renal cell carcinoma (RCC) is a relatively common condition and
when localised it is best treated by nephrectomy. Once the disease
becomes metastatic, treatment options are limited. Current
management has concentrated on the use of immunological
agents, most commonly interferon alpha, which has shown a
survival advantage when compared to medroxyprogesterone
acetate in metastatic disease (Anonymous, 1999). The addition of
interleukin-2 appears to improve the response rate but not the
overall survival (Negrier et al, 1998). Nephrectomy in patients with
metastatic disease appears to have an advantage over the use of
interferon alone (Mickisch et al, 2001). To date, the most
impressive results have been obtained with the combination of
interferon alpha, interleukin-2 and fluorouracil, with response rate
of 30–40% being reported (Allen et al, 2000; Atzpodien et al,
2001). Whether this treatment is a genuine advance over interferon
alone in patients who are relatively fit is currently being examined
by an MRC trial. The use of chemotherapy in RCC has been
disappointing. It has been suggested that this may be because of
the fact that renal cells produce large amounts of multidrug-
resistance protein leading to the efflux of cytotoxics (Tobe et al,
1995; Reese et al, 2000). Chemotherapy in RCC has generally been
based on either fluorouracil or its activated metabolite floxuridine
(Reese et al, 2000). A recent report has demonstrated that the
addition of gemcitabine may improve the response rate to about
20% (Rini and Durras, 2000).
The topoisomerase-1 inhibitor, irinotecan, has shown activity in
renal xenografts (Miki et al, 1998). In other tumour types, synergy
has been demonstrated with either cisplatin (Boku et al, 1999) or
mitomycin C (Gil-Delgado et al, 2001). The combination of
irinotecan, cisplatin and mitomycin C (IPM) is being evaluated at
our institution in several tumour types and appears to show
promising activity (Shamash et al, 2000). This was chosen for use
in patients with biopsy-proven RCC following the failure of
cytokine therapy. Only patients with progressive disease (PD) were
treated; those with residual disease following cytokine therapy
were observed until overt progression as it is clear that long
periods of progression-free survival can be observed in the
presence of metastatic disease and sometimes spontaneous
regressions can be seen (Oliver et al, 1988).
In such an unresponsive tumour, objective response rate may
not be a useful way of assessing activity: the use of time to
progression and the symptomatic response rate may be more
applicable and more important in judging the benefit of therapy.
This paper reports the symptomatic and radiological responses as
well as the time to progression following IPM chemotherapy.
PATIENTS AND METHODS
Patients with histologically confirmed unresectable or metastatic
RCC who were actively progressing despite cytokine-based therapy
(interferon or interferon in combination with interleukin-2 and
fluorouracil) with a performance status of 0–3 and a creatinine
calculated clearance of 450mlmin
 1 were eligible. Patients with
cerebral metastases who were stabilised on steroids were also
eligible. Received 1 May 2002; revised 13 August 2002; accepted 27 January 2003
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lStatistics
The log-rank test was used to compare the progression-free
interval and the overall survival between groups.
The Wilcoxon signed-rank test was used to look at the overall
change in median scores of the quality-of-life (QOL) parameters.
Study design
This was a phase II single institution study for which local research
ethics committee approval was sought and given. The purpose of
this trial was to assess the symptomatic and radiological response
rate, as well as the progression-free survival in patients who
had progressed following cytokine therapy. The progression-
free survival was defined as the time from the initiation of therapy
to the development of new symptoms attributable to PD
with patients being followed up every month following the end
of therapy. For pulmonary disease assessment, routine
chest radiographs were ordered at every clinic visit; for other
sites of disease routine scanning was not undertaken, but in the
event of a new symptom developing an appropriate radiological
investigation was performed, and if this confirmed PD the date of
progression was taken as the date of this symptom and not the date
of the scan.
The treatment consisted of outpatient chemotherapy on a 28-
day cycle. On day 1, patients received oral granisetron 1mg,
dexamethasone 16mg and frusemide 40mg, followed by 1l of 0.9%
NaCl over 1h, followed by bolus mitomycin C 6 mgm
 2, irino-
tecan 70–100mgm
 2 over 30min (a lower dose being chosen if
patients had performance status of 3 or had previous radio-
therapy), and cisplatin 40mgm
 2 in 1l 0.9% NaCl over 1h. On day
15, the therapy was repeated without mitomycin C.
Dose reductions were made as follows. Treatment was given if
the platelets were X100 10
9l
 1 and neutrophils X1 10
9l
 1,
otherwise treatment was delayed by 1 week. Treatment could then
be given if the neutrophils were 41 10
9l
 1 and the platelets
were X75 10
9l
 1 and rising. If the platelet count was X30 and
o75 10
9l
 1 then the treatment was delayed a further week with
mitomycin being given at 50% dose for all subsequent courses. If
the platelet count was o30 10
9l
 1, no further mitomycin was
given. If neutropenic sepsis occurred requiring hospital admission,
then a 20% dose reduction in all subsequent courses of cisplatin
and irinotecan.
CT scans were repeated after two cycles (56 days of therapy) and
if patients had no evidence of progression they proceeded to
receive another two cycles of treatment followed by a further CT
scan. A further two cycles of therapy without mitomycin could be
given at the discretion of the treating physician. Patients were
asked to fill in the EORTC QLQ C30 (þ3) form prior to therapy
and then at monthly intervals at the start of each new cycle of
chemotherapy.
Response assessment
Radiological responses were assessed as follows. Complete
response defined as complete disappearance of radiological
abnormalities, partial response (PR) defined as 450% decrease
in the sums of the products of perpendicular diameters of all
measurable lesions lasting at least 4 weeks. Progressive disease
(PD) was defined as 25% increase in the sum of products of
measurable lesions or the appearance of any new lesion or
reappearance of any lesion that had disappeared. Minor response
(MR) was used to define any tumour, which had radiologically
reduced in size but had not met the criteria of a PR. Stable disease
(SD) was defined as no evidence of radiological response or o25%
increase in the sum of products of measured lesions in the absence
of the appearance of any new lesions. Symptomatic response was
defined as the disappearance of the symptom, for example,
haemoptysis or pain previously attributed to progressive cancer
for which no other therapy (e.g. analgesic) were considered
responsible for.
Patient characteristics
Thirty-three patients were treated between January 1999 and
September 2001. Two patients were not evaluable for response.
One patient stopped therapy after the first dose because of
unacceptable toxicity, the other died of bronchopneumonia 14 days
after starting therapy while neutropenic – both are included in the
progression-free and symptomatic-response analyses (see Table 1).
RESULTS
Quality-of-life (QOL)
Twenty-four of 33 patients returned at least one QOL question-
naire. Fourteen completed a baseline and end of treatment form.
The crude scores were converted into a scale of 0–100, where 100
is excellent QOL. The median, QOL score at the baseline was 62.5,
this fell during therapy by a median of 8.5 (Wilcoxon’s signed-
rank test P¼0.07). There was a slight increase in fatigue,
nausea, vomiting and insomnia scores. All were statistically
nonsignificant. No other changes in the side-effect scores occurred
(see Table 2).
Response to therapy
The objective response to therapy was one out of 31 (3%).
Eight patients (26%) had MR, nine(29%) had SD, 13 (42%)
Table 1 Presentation characteristics
Number of patients 33
Metastatic at diagnosis 14 out of 33
Radical nephrectomy 21 out of 33 (inc. two with
PA nodes)
Median interval radical surgery to
commencing cytokines
(in those 21 patients)
31.4 months (1.6–92.8)
Male:female 29:4
Median age 51 (27–70)
Hb
o12 22
412 11
WBC
o10 23
410 10
Platelets
o450 22
4450 11
LDH
o480 19
4480 14
PS
05
11 6
28
34
No. metastatic sites
11 2
21 4
37
Median duration of disease 23.6 months (3.1–162.4)
o2 years 16
42 years 17
Median duration of metastases 15.6 months (0.2–80.3)
o1 year 13
41 year 20
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lhad PD. Twenty-eight had symptoms at the start of IPM, of
whom 17 improved (61%). The overall progression-free
interval (PFI) was 4.4 months compared to 3.9 months for the
prior cytokine treatment (P¼0.99). Those who had a sympto-
matic response had an improved PFI (6.2 vs 1.8 months,
P¼0.001). The median survival for all patients from the start of
chemotherapy was 9.2 months. Thirteen (39%) were progression
free at 6 months.
Those who had a symptomatic response had improved survival
(10.8 vs 5.7 months, P¼0.001), those who had radiologically stable
disease or better also showed enhanced survival (14.3 vs 5.7
months for those with progressive disease, P¼0.001) (see Figures
1 and 2).
Comparison of IPM responses with prior response to
cytokines
All patients had received prior cytokine therapy, 24 received
interferon monotherapy and nine received triple therapy with
interferon/interleukin-2/fluorouracil. There was no suggestion of
any advantage for the triple therapy-treated patients (median PFI
of 2.8 (triple therapy) vs 3.9 months). Fifteen out of 30 (50%)
assessable patients (of the three nonassessable patients, two died
prior to response assessment, one received cytokines in the
adjuvant setting as part of a clinical trial) had at least SD to
cytokines, as expected their PFI with cytokines was prolonged
(10.2 vs 2.4 months, P¼0.001). Similarly, those who had a
symptomatic response (six out of 25, 24%) to cytokines had a
trend to prolonged PFI with them (10.2 vs 3.7 months, P¼0.09).
Twenty-eight patients were evaluable for response for both
cytokines and IPM. Fifteen had radiological progression during
cytokines of whom nine (67%) subsequently had at least SD to
IPM. Twenty-one of 28 had symptoms at the start of cytokines; of
these, 15 did not have a symptomatic response to cytokines but 11
(73%) went on to have a symptomatic response to IPM, suggesting
a lack of crossresistance between IPM and prior cytokine therapy
(see Table 3).
Toxicity
There was one treatment-related death, from bronchopneumonia
while neutropenic. The most common grade 3–4 toxicity was
malaise, which occurred in 17% of cycles. Neutropenia (19%) was
frequently asymptomatic. There were 19 admissions for toxicity.
Despite day case cisplatin with limited prehydration, there were no
cases of severe nephrotoxicity (see Table 4).
Prognostic factors
The following pretreatment prognostic factors were studied: age,
sex, performance status, white blood cell count, platelets,
haemoglobin, lactate dehydrogenase, number of metastatic sites,
presence of liver or central nervous metastases vs the presence of
Table 2 QLQ scores from start to end of treatment
No. of patients
Change in
Better Same Worse score
QOL Quality of life 3 3 8  8.5
PF Physical function 2 10 2 0
RF Role function 6 6 0 0
EF Emotional function 5 6 3 0
CF Control function 1 7 6 0
SF Social function 3 6 5 0
FA Fatigue 1 5 8 +11.0
NV Nausea and vomiting 2 5 7 +8.5
PA Pain 3 8 3 0
DY Dyspnoea 1 7 6 0
SL Insomnia 2 5 7 +16.5
AP Appetite 1 7 6 0
CO Constipation 2 9 3 0
DI Diarrhoea 1 8 5 0
FI Financial difficulties 5 8
Figure 1 Chest radiograph prior and post-IPM therapy.
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Figure 2 Overall survival by presence or absence of a symptomatic
response.
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llung/nodal metastases only; with the exception of haemoglobin
none had prognostic significance. A pretreatment haemoglobin of
4120gl
 1 predicted for enhanced overall survival –see Figure 3
(10.8 vs 6.4 months, P¼0.03).
DISCUSSION
The study shows a moderate level of activity from IPM
chemotherapy in patients with RCC who would normally be
considered refractory to all current treatment. The number of
patients experiencing symptomatic benefit was encouraging as was
the fact that the progression-free survival was equal to that of the
trial cytokine treatment in these patients (although the numbers
were small) was also of note. The number progression free at 6
months was at least comparable to that seen with cytokines and the
lack of crossresistance to cytokines is clearly interesting.
Patients with responses of SD or greater or those experiencing a
symptomatic response, clearly had longer progression-free and
overall survival. Interestingly, one patient who had a symptomatic
Table 3 Comparison between IPM response and response to previous cytokine therapy
Cytokines
IFN monotherapy 24
IFN combination therapy 9
Median interval cytokines to commencing IPM 5.9 months (1–62)
Cytokines IPM
Response
Adjuvant 1 0
PR 1 1
MR 3 8
SD 11 9
PD 15 13
NE 2 2
PR or better One out of 30 (3%) One out of 31 (3%)
SD or better 15 out of 30 (50%) 18 out of 31 (58%)
Symptomatic
Response Six out of 25 (24%) 17 out of 28 (61%)
Median progression-free interval
Overall 3.9 months 4.4 months
(a) SD or better 10.2 months 6.9 months
(b) PD 2.4 months 1.9 months
P-value (a vs b) o0.001 o0.001
(c) Symptomatic response 10.2 months 6.2 months
(d) No symptomatic response 3.7 months 1.8 months
P-value (c vs d) 0.09 o0.001
Symptomatic response to cytokines vs IPM Cytokine symptomatic response
No Yes Total
IPM symptomatic response No 4 1 5
Yes 11 5 16
Total 15 6 21
Table 4 Toxicity in IPM: by course, showing the percentage of courses
complicated by WHO grade grade 3–4 toxicity and the number of
patients who experienced this
No. of
courses
% Courses
grade 3–4 No. of patients
Malaise 87 17 10
Dyspnoea 85 7 5
Infection 87 6 4
Diarrhoea 87 1 1
Anorexia 85 2 2
Nausea 87 1 1
Vomiting 86 0 0
Stomatitis 82 0 0
Neutropenia 89 19 12
Thrombocytopenia 90 1 1
Hb/WBC 90 10 5
Renal 80 0 0
Seventeen patients were admitted because of toxicity, of whom two were admitted
on two occasions.
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Figure 3 Overall survival by haemaglobin greater than or less than
120gl
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lresponse from a vertebral metastases leading to cord compression
and paraplegia despite radiotherapy, improved sufficiently on
chemotherapy to be able to regain the ability to walk and for his
steroids to be reduced to a maintenance dose of 5mg of
prednisolone a day; however, as he developed a new lung lesion
during this time, he had to be classed as having had PD.
The level of haemoglobin was the only prior investigation,
which had prognostic value. This has also been seen with cyto-
kines in RCC –indeed a raised haemoglobin appears to confer an
even better prognosis (Janik et al, 1993). The reason for this is
unclear and not related to erythropoietin levels (Ljungberg et al,
1992).
Responses seem independent of pre-existing performance
status, duration of disease, number of metastatic sites. Quality-
of-life analysis appeared to show that overall there was little
change in QOL from therapy. Unfortunately, only two-thirds of
patients completed at least two QOL forms, which clearly reduced
the impact of this tool. In particular, it would have been useful to
know what happened to QOL in the months following the end of
chemotherapy. Those who had a symptomatic response and
therefore much greater survival appeared to have similar QOL
on treatment as those who did not respond at all. It can be
concluded that a trial of two cycles of therapy in this patient group
can be considered without a detrimental effect on QOL.
It has been recently shown that nephrectomy in patients with
metastatic disease offered a survival advantage over cytokine
therapy alone (Mickisch et al, 2001). A majority of patients in this
group already had nephrectomies; whether palliative nephrectomy
either post or prior to chemotherapy would improve things further
remains to be determined.
To date the most impressive report of chemotherapy in renal
cancer has used the combination of fluorouracil and gemcitabine.
The partial response rate was 17% (Rini and Durras, 2000), not all
patients had prior cytokine therapy, and it is not clear that all the
patients were actively progressing at the time of treatment and this
makes the interpretation of the impressive 28 week progression-
free survival more difficult, especially as the overall median
survival was 11.6 months (compared to 9.6 months in this study).
The decision to observe patients with stable metastases rather than
give immediate therapy contributed to the relatively long duration
of metastatic disease prior to treatment in this cohort. This may be
of importance in studies of renal cancer where long periods of time
with stable metastatic disease can be encountered.
Allogeneic transplantation has been proposed as an attractive
therapy for cytokine refractory RCC (Childs et al, 2000). The
requirement for a matched sibling donor clearly restricts the
potential of this approach as does the observation that it takes
approximately 3 months to have any significant graft vs tumour
effect to be evident. Patients with rapidly PD would not be suitable.
This procedure may be considered in patients progressing despite
cytokines, if they have stabilised during chemotherapy.
Alternative approaches have included the use of thalidomide;
although its effect on this disease remains unclear, occasional
dramatic responses have been seen (Stebbing et al, 2001). It has
been suggested that this works as an antiangiogenic agent,
although direct proof of this is lacking. In this cohort following
IPM, seven patients went on to receive thalidomide; however, all
but one progressed rapidly on it.
This study illustrates some of the problems in evaluating
therapy in metastatic renal cancer. The objective response rate was
low, but the improvement in symptoms and progression-free
survival was encouraging, particularly as all patients had been
progressing prior to therapy being started.
Future studies aiming to integrate cytokine therapy with
chemotherapy, or fluorouracil or gemcitabine into an irinotecan-
based regimen are clearly attractive as synergy has been
demonstrated in other tumour types, for example, melanoma,
where recently the advantages of biochemotherapy over standard
cytotoxic therapy in terms of objective response and time to
progression have been confirmed in a multicentre Phase III study
(Eton et al, 2002). Such approaches may be particularly helpful in
those predicted to have poor responses to cytokines alone, namely
those with sarcomatoid tumours and those with a poorer
performance status.
In conclusion, IPM chemotherapy offers modest but real
symptomatic benefits in cytokine refractory renal cancer. Those
with a normal level of haemoglobin prior to therapy appear to
benefit the most, and those patients who have symptomatic
responses or radiological stabilisation appear to have prolonged
survival, the progression-free interval is comparable to the prior
cytokine therapy and a degree of non-crossresistance has been
demonstrated.
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